Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun-Qing Liang

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 25, 2021
AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airwayShun-Qing Liang, Christopher J Walkey, Alexa E Martinez, et al.
Nature Methods|May 8, 2023
Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tagShun-Qing Liang, Pengpeng Liu, Karthikeyan Ponnienselvan, et al.
Nature Communications|April 10, 2021
Improved prime editors enable pathogenic allele correction and cancer modelling in adult micePengpeng Liu, Shun-Qing Liang, Chunwei Zheng, et al.
British Journal of Cancer|June 21, 2018
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesotheliomaDuo Xu, Shun-Qing Liang, Haitang Yang, et al.
Molecular Cancer Therapeutics|November 8, 2019
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural MesotheliomaDuo Xu, Shun-Qing Liang, Haitang Yang, et al.
Cancers|October 11, 2019
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural MesotheliomaDuo Xu, Haitang Yang, Zhang Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesotheliomaDuo Xu, Shun-Qing Liang, Min Su, et al.
EMBO Molecular Medicine|July 24, 2025
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesotheliomaDuo Xu, Yanyun Gao, Shengchen Liu, et al.
RNA (New York, N.Y.)|May 28, 2025
Absolute quantification of mammalian microRNAs for therapeutic RNA cleavage and detargetingCarolyn Kraus, Jiayi Wang, Haiying Zheng, et al.
EMBO Molecular Medicine|January 16, 2026
Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesotheliomaDuo Xu, Yanyun Gao, Shengchen Liu, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 25, 2021
AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airwayShun-Qing Liang, Christopher J Walkey, Alexa E Martinez, et al.
Nature Methods|May 8, 2023
Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tagShun-Qing Liang, Pengpeng Liu, Karthikeyan Ponnienselvan, et al.
Nature Communications|April 10, 2021
Improved prime editors enable pathogenic allele correction and cancer modelling in adult micePengpeng Liu, Shun-Qing Liang, Chunwei Zheng, et al.
British Journal of Cancer|June 21, 2018
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesotheliomaDuo Xu, Shun-Qing Liang, Haitang Yang, et al.
Molecular Cancer Therapeutics|November 8, 2019
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural MesotheliomaDuo Xu, Shun-Qing Liang, Haitang Yang, et al.
Cancers|October 11, 2019
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural MesotheliomaDuo Xu, Haitang Yang, Zhang Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesotheliomaDuo Xu, Shun-Qing Liang, Min Su, et al.
EMBO Molecular Medicine|July 24, 2025
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesotheliomaDuo Xu, Yanyun Gao, Shengchen Liu, et al.
RNA (New York, N.Y.)|May 28, 2025
Absolute quantification of mammalian microRNAs for therapeutic RNA cleavage and detargetingCarolyn Kraus, Jiayi Wang, Haiying Zheng, et al.
EMBO Molecular Medicine|January 16, 2026
Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesotheliomaDuo Xu, Yanyun Gao, Shengchen Liu, et al.
Pageof 4